Topical Cannabidiol for Antidepressant-Induced Sexual Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for antidepressant-induced female sexual dysfunction are ineffective, leading to significant adverse effects and treatment discontinuation, with limited pharmacological options and potential adverse drug interactions with systemic cannabinoid administration.
Innovation Solution
Topical application of cannabidiol (CBD)-containing compositions to the female genital area, which acts peripherally to enhance sexual function and alleviate antidepressant-induced sexual dysfunction, including difficulties with arousal, lubrication, and orgasm, without the adverse interactions associated with systemic administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic cannabinoid administration is used to treat antidepressant-induced sexual dysfunction, then therapeutic effect is achieved, but adverse drug interactions occur
Solution Approach 1:
The invention divides the administration approach into localized topical application versus systemic administration. By applying CBD topically to the genital area, the treatment is segmented to act only where needed, avoiding systemic circulation and potential drug interactions while maintaining therapeutic efficacy for sexual dysfunction.
Solution Approach 2:
The invention applies CBD locally to the genital area rather than systemically. This local quality approach concentrates the therapeutic effect where it is needed (improving lubrication, arousal, and orgasm) while minimizing exposure to other medications and reducing the risk of adverse drug interactions.
2Reliability
If antidepressants are used to treat depression, then depressive symptoms are relieved, but sexual dysfunction occurs
Solution Approach 1:
The invention introduces CBD as an intermediary substance that counteracts the sexual dysfunction caused by antidepressants. The topical CBD application serves as a mediator that restores sexual function (lubrication, arousal, orgasm) without interfering with the antidepressant's effectiveness in treating depression.
Solution Approach 2:
The invention converts the harmful side effect of antidepressant-induced sexual dysfunction into a treatable condition using topical CBD. By applying CBD locally, the treatment transforms the adverse effect into a targeted therapeutic opportunity, improving sexual function while maintaining antidepressant therapy.
3Reliability
If topical CBD is applied to enhance sexual function, then sexual function improves, but systemic absorption may occur
Solution Approach 1:
The invention uses partial action by applying CBD topically to achieve sufficient therapeutic effect locally without requiring complete systemic absorption. The localized application provides enough CBD to improve sexual function (lubrication, arousal, orgasm) while minimizing the quantity that enters systemic circulation.
Data Source
AI summary
The invention relates to compositions and methods containing hemp and/or Cannabis-derived cannabidiol (CBD) for topical use in treating female sexual dysfunction induced by antidepressants, including, e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin/norepinephrine reuptake inhibitors (SNRIs), and other anti-depressants.